Development of a broadly accessible Venezuelan equine encephalitis virus replicon particle vaccine platform

Journal of Virology

Volumn 92, Issue 11, 2018, Pages

  Agnihothram, Sudhakar ^a   Menachery, Vineet D ^a,b   Yount, Boyd L ^a   Lindesmith, Lisa C ^a   Scobey, Trevor ^a   Whitmore, Alan ^c   Schäfer, Alexandra ^a   Heise, Mark T ^c   Baric, Ralph S ^a,c  

^a University of North Carolina at Chapel Hill   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aged; Coronavirus; Heterologous; Norovirus; Vaccine; VEE replicon; VRP

Indexed keywords

LIVE VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; V 3000S; V 3014S; V 3526S; VENEZUELAN EQUINE ENCEPHALITIS VIRUS VACCINE; VIRUS VACCINE; VRP 3526; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CORONAVIRINAE; DRUG EFFICACY; DRUG SAFETY; FEMALE; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; NOROVIRUS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPLICON; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINE PRODUCTION; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS LIKE AGENT; VIRUS PARTICLE; AGING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; CHLOROCEBUS AETHIOPS; GENETICS; HUMAN; IMMUNOLOGY; SARS CORONAVIRUS; VENEZUELAN EQUINE ENCEPHALITIS; VERO CELL LINE; VIROLOGY; ZOONOSIS;

AGING; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, ATTENUATED; VERO CELLS; VIRAL VACCINES; ZOONOSES;

EID: 85046897752     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00027-18     Document Type: Article

References (45)

1. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399. https://doi.org/10.1126/science.1085952
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953-1966. https://doi.org/10.1056/NEJMoa030781
3. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3:e00473-12
4. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. https://doi.org/10.1056/NEJMoa1211721
5. Anthony SJ, Gilardi K, Menachery VD, Goldstein T, Ssebide B, Mbabazi R, Navarrete-Macias I, Liang E, Wells H, Hicks A, Petrosov A, Byarugaba DK, Debbink K, Dinnon KH, Scobey T, Randell SH, Yount BL, Cranfield M, Johnson CK, Baric RS, Lipkin WI, Mazet JA. 2017. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. mBio 8:e00373-17. https://doi.org/10.1128/mBio.00373-17
6. Menachery VD, Yount BL, Jr, Sims AC, Debbink K, Agnihothram SS, Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR, Swanstrom J, Sheahan TP, Pickles RJ, Corti D, Randell SH, Lanzavecchia A, Marasco WA, Baric RS. 2016. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A 113:3048-3053. https://doi.org/10.1073/pnas.1517719113
7. Menachery VD, Yount BL, Jr, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS. 2015. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 21:1508-1513. https://doi.org/10.1038/nm.3985
8. Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, Baric R. 2008. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J Virol 82:2274-2285. https://doi.org/10.1128/JVI.02041-07
9. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18:1820-1826. https://doi.org/10.1038/nm.2972
10. Tonkin DR, Whitmore A, Johnston RE, Barro M. 2012. Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine 30: 4532-4542. https://doi.org/10.1016/j.vaccine.2012.04.030
11. Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, West A, Donaldson E, Curtis K, Johnston R, Baric R. 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3:e525. https://doi.org/10.1371/journal.pmed.0030525
12. MacDonald GH, Johnston RE. 2000. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74:914-922. https://doi.org/10.1128/JVI.74.2.914-922.2000
13. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401. https://doi.org/10.1006/viro.1997.8878
14. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD. 2009. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28: 484-493. https://doi.org/10.1016/j.vaccine.2009.09.135
15. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, Moe CL, Baric RS. 2006. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24:5220-5234. https://doi.org/10.1016/j.vaccine.2006.03.080
16. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B. 2004. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78: 3572-3577. https://doi.org/10.1128/JVI.78.7.3572-3577.2004
17. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS. 2011. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 85:217-230. https://doi.org/10.1128/JVI.01805-10
18. White LJ, Sariol CA, Mattocks MD, Wahala WM, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI, de Silva A, Johnston RE. 2013. An alphavirus vector based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol 87:3409-3424. https://doi.org/10.1128/JVI.02298-12
19. Kamrud KI, Alterson K, Custer M, Dudek J, Goodman C, Owens G, Smith JF. 2010. Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle. J Gen Virol 91:1723-1727. https://doi.org/10.1099/vir.0.020081-0
20. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. https://doi.org/10.1006/viro.2000.0546
21. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3:e5. https://doi.org/10.1371/journal.ppat.0030005
22. Fine DL, Roberts BA, Terpening SJ, Mott J, Vasconcelos D, House RV. 2008. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 26: 3497-3506. https://doi.org/10.1016/j.vaccine.2008.04.044
23. Davis NL, Brown KW, Greenwald GF, Zajac AJ, Zacny VL, Smith JF, Johnston RE. 1995. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212: 102-110. https://doi.org/10.1006/viro.1995.1458
24. Pratt WD, Davis NL, Johnston RE, Smith JF. 2003. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21:3854-3862. https://doi.org/10.1016/S0264-410X(03)00328-1
25. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. 2008. HIV vaccine research: the way forward. Science 321:530-532. https://doi.org/10.1126/science.1161000
26. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL. 2010. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 28:3143-3151. https://doi.org/10.1016/j.vaccine.2010.02.056
27. Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, Baker DC, Powers AM, Bowen RA. 2007. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 25:1868-1876. https://doi.org/10.1016/j.vaccine.2006.10.030
28. Rao V, Hinz ME, Roberts BA, Fine D. 2006. Toxicity assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526. Vaccine 24:1710-1715
29. Rao V, Hinz ME, Roberts BA, Fine D. 2004. Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526. Vaccine 22:2667-2673. https://doi.org/10.1016/j.vaccine.2003.09.041
30. Frieman M, Yount B, Agnihothram S, Page C, Donaldson E, Roberts A, Vogel L, Woodruff B, Scorpio D, Subbarao K, Baric RS. 2012. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J Virol 86:884-897. https://doi.org/10.1128/JVI.05957-11
31. Rockx B, Donaldson E, Frieman M, Sheahan T, Corti D, Lanzavecchia A, Baric RS. 2010. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 201:946-955. https://doi.org/10.1086/651022
32. Rani M, Bolles M, Donaldson EF, Van Blarcom T, Baric R, Iverson B, Georgiou G. 2012. Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J Virol 86:9113-9121. https://doi.org/10.1128/JVI.00233-12
33. Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, Miller CJ, Johnston RE. 2011. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone in rhesus macaques. Vaccine 29:931-940. https://doi.org/10.1016/j.vaccine.2010.11.024
34. Tews BA, Meyers G. 2017. Self-replicating RNA. Methods Mol Biol 1499: 15-35. https://doi.org/10.1007/978-1-4939-6481-9_2
35. Pushko P, Lukashevich IS, Weaver SC, Tretyakova I. 2016. DNA-launched live-attenuated vaccines for biodefense applications. Expert Rev Vaccines 15:1223-1234. https://doi.org/10.1080/14760584.2016.1175943
36. Zhao J, Legge K, Perlman S. 2011. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Investig 121:4921-4930. https://doi.org/10.1172/JCI59777
37. Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. 2016. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44:1379-1391. https://doi.org/10.1016/j.immuni.2016.05.006
38. Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, Denison MR, Geisbert TW, Baric RS. 2003. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 100:12995-13000. https://doi.org/10.1073/pnas.1735582100
39. Yount B, Roberts RS, Sims AC, Deming D, Frieman MB, Sparks J, Denison MR, Davis N, Baric RS. 2005. Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol 79:14909-14922. https://doi.org/10.1128/JVI.79.23.14909-14922.2005
40. Menachery VD, Yount BL, Josset L, Gralinski LE, Scobey T, Agnihothram S, Katze MG, Baric RS. 2014. Attenuation and restoration of SARS-CoV mutant lacking 2= O methyltransferase activity. J Virol 88:4251-4264. https://doi.org/10.1128/JVI.03571-13
41. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A doubleinactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 85: 12201-12215. https://doi.org/10.1128/JVI.06048-11
42. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, Nagel J, Johnson JB, Agnihothram S, Gates JE, Frieman MB, Baric RS, Donaldson EF. 2012. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol 86:12816-12825. https://doi.org/10.1128/JVI.00906-12
43. Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, Heise MT. 2008. MyD88 is required for protection from lethal infections with a mouse-adapted SARS-CoV. PLoS Pathog 4:e1000240. https://doi.org/10.1371/journal.ppat.1000240
44. Debbink K, Costantini V, Swanstrom J, Agnihothram S, Vinje J, Baric R, Lindesmith L. 2013. Human norovirus detection and production, quantification, and storage of virus-like particles. Curr Protoc Microbiol 31: 15K.1.1-15K.1.45
45. Lindesmith LC, Costantini V, Swanstrom J, Debbink K, Donaldson EF, Vinje J, Baric RS. 2013. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 87:2803-2813. https://doi.org/10.1128/JVI.03106-12